RxDoctor Payments Data

John Rice, DO

Family Medicine · Checotah, OKNPI 1417021353

Payments from drug & device makers

$228in general payments, 2019–2025

Across 10 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$85
  • Lilly USA, LLC$60
  • Novo Nordisk$24
  • Mylan Specialty L.p.$19
  • Eisai Inc.$16
  • Pfizer$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$14363%
  • Education$8537%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$228 in reported general payments places this provider in the 40th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$391,955
Medicare patients
596
Services billed
21,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$213,086
EliquisApixaban222$186,090
JardianceEmpagliflozin39$56,548
XareltoRivaroxaban50$53,066
JanuviaSitagliptin Phosphate28$29,387
EntrestoSacubitril/Valsartan29$23,008
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$22,241
MounjaroTirzepatide14$17,405
TradjentaLinagliptin14$13,391
SymbicortBudesonide/Formoterol Fumarate25$13,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,687
Breo ElliptaFluticasone/Vilanterol21$11,544
Rosuvastatin Calcium479$9,087
Omeprazole463$8,800
Gabapentin383$8,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$213,086152 claims
PfizerEliquis, Premarin, Retacrit$13$198,250253 claims
Lilly USA, LLCMounjaro$60$17,40514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Checotah

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →